ReviewClinical microbiology reviews2018
Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.
Review in Clinical microbiology reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04781257 (Early Risk Assessment in TB contactS by New Diagnostic tEsts), which is not on this map. Cited by 339 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Risk Assessment in TB contactS by New Diagnostic tEsts
Who cites it
339 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Evaluating the diagnostic accuracy of QIAreach QuantiFERON-TB compared to QuantiFERON-TB Gold Plus for tuberculosis: a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Subclinical tuberculosis: a meta-analysis of prevalence and scoping review of definitions, prevalence and clinical characteristics.European respiratory review : an official journal of the European Respiratory Society · 2024Pooled it
- Systematic review of innate immune responses againstFrontiers in immunology · 2024Pooled it
- Gene signature discovery and systematic validation across diverse clinical cohorts for TB prognosis and response to treatment.PLoS computational biology · 2023Pooled it
- Time to diagnosis and treatment of pulmonary tuberculosis in indigenous peoples: a systematic review.BMC infectious diseases · 2023Pooled it
- A Clinical Multicenter Trial of Recombinant Human Interferon Gamma in Tuberculosis (GAM2022): Experience with the Use of Human Recombinant Interferon Gamma in TB Practice.Infectious disorders drug targets · 2025Trial
- Community-based "X-ray+Xpert® MTB/RIF ultra pooling test" case-finding strategy among high-risk groups in rural areas: a prospective application study.Emerging microbes & infections · 2026Article
- Responding to a protracted tuberculosis outbreak: lessons from multiple rounds of investigation in a Chinese boarding school.Annals of medicine · 2026Article
- Post-Tuberculosis Lung Disease: Clinicopathologic Insights, Diagnosis, Prevention, and Management.MedComm · 2026Review
- Novel RT‒qPCR-based blood signatures for the diagnosis of pulmonary tuberculosis.Scientific reports · 2026Article
- Targeting Latent Tuberculosis: Immunogenic Evaluation of aInternational journal of molecular sciences · 2026Article
- Review
- Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis.Nature communications · 2026Article
- Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Asymptomatic Tuberculosis: The Silent Face of the Disease Among Migrants and Refugees and the Challenges in Brazil.Journal of immigrant and minority health · 2026Article
- Treatment outcomes and risk factors for unfavorable results among older asymptomatic pulmonary tuberculosis patients in China, 2021-2024.BMC geriatrics · 2026Article
- Community-based chest X-ray screening versus symptom-based case presentation in the elderly: evidence from three consecutive years of data.BMC geriatrics · 2026Article
- Associations Between QuantiFERON-TB Gold Plus IFNγ Concentrations and Progression to Symptomatic Tuberculosis in Global High-Burden TB Settings.Open forum infectious diseases · 2026Article
- Immune endotypes in tuberculosis: Keys to decoding disease complexity.Journal of internal medicine · 2026Review
- The host immune response to Mycobacterium tuberculosis determining protection or disease progression.Nature immunology · 2026Review
279 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Tuberculosis (TB) is the leading infectious cause of mortality worldwide, due in part to a limited understanding of its clinical pathogenic spectrum of infection and disease. Historically, scientific research, diagnostic testing, and drug treatment have focused on addressing one of two disease states: latent TB infection or active TB disease. Recent research has clearly demonstrated that human TB infection, from latent infection to active disease, exists within a continuous spectrum of metabolic bacterial activity and antagonistic immunological responses. This revised understanding leads us to propose two additional clinical states: incipient and subclinical TB. The recognition of incipient and subclinical TB, which helps divide latent and active TB along the clinical disease spectrum, provides opportunities for the development of diagnostic and therapeutic interventions to prevent progression to active TB disease and transmission of TB bacilli. In this report, we review the current understanding of the pathogenesis, immunology, clinical epidemiology, diagnosis, treatment, and prevention of both incipient and subclinical TB, two emerging clinical states of an ancient bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.